



## PD-1/PD-L1 non-small cell lung cancer update for 2025 for Humana Medicare Advantage members

### Background

Humana's Pharmacy and Therapeutics committee, which is comprised of physicians and pharmacists from various specialties, reviews and approves Humana's medical drug strategies to ensure our prescription drug changes align with the latest clinical standards. Based on clinical guidelines and literature, Humana will implement a new drug strategy for 2025 for the treatment of non-small cell lung cancer (NSCLC).

### Medicare Part B step strategy details for 2025

Starting Jan. 1, 2025, Humana's Medicare Part B step strategy will apply to frontline metastatic NSCLC with a requirement to use the preferred product, Libtayo®. The Medicare Part B step strategy only applies to new starts.

- **Preferred product:** Libtayo
- **Nonpreferred products:** Keytruda®, Opdivo®, Tecentriq®, Imfinzi®, Imjudo® and Yervoy®

### Summary

Humana prioritizes the well-being of our members by ensuring affordable access to clinically appropriate and cost-effective medications. Our directions can be found below.

Existing utilizers of Keytruda, Opdivo, Tecentriq, Imfinzi, Imjudo or Yervoy for NSCLC that are currently in a Medicare Advantage plan with Humana:

- If there are claims within the previous 365 days for these products, no additional action is needed from providers at this time.

New utilizers of Keytruda, Opdivo, Tecentriq, Imfinzi, Imjudo or Yervoy for NSCLC:

- Providers will need to provide a medical reason why Libtayo single agent (for PD-L1 ≥ 50%) or Libtayo in combination with platinum-based chemotherapy (for any PD-L1 status) cannot be initiated.

Prescribers with questions regarding this change can call:

- **Evolent:** 844-926-4528, option 3, Monday – Friday, 8 a.m. – 8 p.m., and Saturday, 8 a.m. – 5 p.m., Eastern time
- **OncoHealth:** 888-916-2616, Monday – Friday, 8:30 a.m. – 8 p.m., and Saturday, 8:30 a.m. – 6 p.m., Eastern time
- **Humana Clinical Pharmacy Review Medical Team:** 866-461-7273, Monday – Friday, 8 a.m. – 11 p.m., Eastern time

